Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Sciences Index Present Pharma Integrates 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Strategically transforming Pharma business relationships.

Date/Venue
•    Pharma Integrates 2013 will be held on Tuesday 26th and Wednesday 27th November at the Riverbank Park Plaza, London. Further details available at www.lifesciencesindex.com.

Format
•    Following the success of the inaugural Pharma Integrates 2012, PI 2013 will retain the one and a half day conference format. Chairman Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals will be opening the half day series of keynotes and plenary panel discussions. The second day will include multiple tracks, with the majority of the sessions being interactive panel discussions to stimulate information exchange and organic discussion.

Theme
•    The overarching theme of Pharma Integrates is ‘Strategically transforming Pharma business relationships’,  with presentations and panel discussions addressing key industry issues from both an early and late product life cycle perspective. In 2013, we will examine how strategic relationships are evolving and increasingly becoming a source of mutual competitive advantage. Further how such collaborations are supporting innovation, productivity, differentiation and profitable growth. Topics to be addressed will include Risk Sharing, Biosimilars, Pricing, Partnering, Open Innovation and Pharma Intellectual Property.

•    Further details of Day One and Day Two Agenda available here: http://www.lifesciencesindex.com/pharma-integrates-2013-agenda

What to expect from Pharma Integrates 2013

•    Unique panel discussion format ensuring the ultimate interactive experience.

•    Blockbuster topics that straddle a complementary profile of industry stakeholders.

•    Strategically led content dedicated to senior level strategists

•    Unrivalled networking opportunities with champagne reception, luncheon and extended breaks throughout the conference timetable.

Attendee Feedback from Pharma Integrates 2012

“Relevant, good speakers, right size. Made many new contacts – thanks!” Neil Baker, Pfizer.

“Nothing similar in the EU. Panel discussion approach very successful.” Laura Walsh, 3M.

“The event attracted high level delegates and decision makers and was very informal. Good presentations, very entertaining.” Heather Brunyee, Wockhardt.

“Enjoyed the level of attendees, good mix of stakeholders- all with a passion to improve the industry. We now need to deliver!” David Tudbury, Catalent.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!